

Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab

NCT07061080

Status	RECRUITING
Phase	Phase 2
Sponsor	Grupo Espanol de Tumores Neuroendocrinos
Enrollment	87 participants

Key Eligibility Criteria

Inclusion (29)

- Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent.
- Patient is e 18 years of age.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- Histologically confirmed neuroendocrine carcinomas (NECs) of the digestive system or unknown primary origin.
- Note: Carcinomas of pulmonary origin are not eligible.

... and 24 more (see full listing online)

Exclusion (30)

- The following endocrine tumor types may not be included:
- Paraganglioma, adrenal, thyroid parathyroid or pituitary endocrine tumors,
- Large or small cell lung neuroendocrine carcinoma of the lung,
- Neuroendocrine tumors (NETs) of the gastrointestinal tract or unknown origin (i.e. well differentiated tumors)
- History of other malignancy within the past 2 years prior to first dose of tarlatamab except:

... and 25 more (see full listing online)

Locations (19 total)

Brest University Hospital Centre, Brest, Brest, France
Centre Régional de Lutte Contre le Cancer Institut Bergonié (Bordeaux), Bordeaux, Cedex, France
Centre Oscar Lambret, Lille, Lille, France

... and 16 more locations